Licensing
BioInvent International AB has signed a license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies against up to five therapeutic targets discovered using BioInvent’s n-CoDeR library.
As part of the deal, Mitsubishi Tanabe will be granted access to BioInvent’s discovery and development technology platform, and in return the Swedish company will receive an undisclosed upfront access fee, annual maintenance fees and royalties on any commercialised products. The agreement follows on an existing research license and a feasibility study concluded earlier this year.
The n-CoDeR library contains more than 20 billion highly diverse, fully human antibody fragments created using BioInvent’s patented approach, to generate antibodies with high affinity and selectivity.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
